Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy.

Frontiers in oncology（2023）

引用 0|浏览18

暂无评分

摘要

[This corrects the article DOI: 10.3389/fonc.2021.621992.].

查看译文

关键词

osimertinib,tp53 r273c,advanced nsclc patients,clinical multicentre study,corrigendum

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要